Subjects with preexisting cardiovascular symptoms who were r

Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9670 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. The subjects were randomly assigned to subitramine (4914 subjects) or a placebo (4756 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 542 subjects in the subitramine group and 504 subjects in the placebo group.

Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome?

State hypotheses, find the test statistic and the P-value.

Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9670 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. The subjects were randomly assigned to subitramine (4914 subjects) or a placebo (4756 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 542 subjects in the subitramine group and 504 subjects in the placebo group.

Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome?

State hypotheses, find the test statistic and the P-value.

Because the P-value is large, there is a difference in the proportion of \"primary outcomes\" between subitramine and placebo.

Solution

Subjects with preexisting cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular

Get Help Now

Submit a Take Down Notice

Tutor
Tutor: Dr Jack
Most rated tutor on our site